Skip to main content
SpringerLink
Log in

Interactions Between Calcium Intake and Antiresorptive Therapy in Osteoporosis

  • Chapter
Nutritional Aspects of Osteoporosis

Part of the book series: Proceedings in the Serono Symposia USA Series ((SERONOSYMP))

  • 125 Accesses

Abstract

An adequate calcium intake has been shown to be beneficial to bone mass at all stages of life, however most societies have calcium intakes well below the recommended levels. Increased calcium intake maximizes peak bone mass and reduces bone loss in premenopausal women (1–4). Furthermore, calcium supplementation reduces the rate of bone loss in postmenopausal women by approximately 0.8% per year when compared with untreated women with the effect of calcium less evident in the years immediately following menopause (5, 6). As calcium effects are generally significantly less than those of standard antiresorptive therapy, calcium cannot replace antiresorptive therapy (7, 8). However, what is unknown is whether additional calcium can provide a benefit to bone mineral density (BMD) when superimposed on standard antiresorptive therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Johnston CC, Jr, Miller JZ, Slemenda CW, Reister TK, Hui S, Christian JC, et al. Calcium supplementation and increases in bone mineral density in children. N Engl J Med 1992; 327: 82–7.

    Article  PubMed  Google Scholar 

  2. Nieves JW, Golden AL, Siris E, Kelsey JL, Lindsay R. Teenage and current calcium intake are related to bone mineral density of the hip and forearm in women aged 30–39. Am J Epidemiol 1995; 141: 342–51.

    Article  PubMed  CAS  Google Scholar 

  3. Welton DC, Kemper CG, Post B, Van Staveren WA. A meta-analysis of the effect of calcium intake on bone mass in young and middle aged females and males. J Nutr 1995; 125: 2802–13.

    Google Scholar 

  4. Nowson CA, Green RM, Guest CS, Larkins RG, Sherwin AJ, Kaymakci B, et al. The effect of calcium supplementation on bone mass in adolescent female twins. Challenges of Modern Medicine 1995; 7: 169–75.

    CAS  Google Scholar 

  5. Cumming RG. Calcium intake and bone mass: a quantitative review of the evidence. Calcif Tissue Int 1990; 47: 194–201.

    Article  PubMed  CAS  Google Scholar 

  6. Dawson-Hughes B. Calcium supplementation and bone loss: a review of controlled clinical trials. Am J Clin Nutr 1991; 54: 2745–80S.

    Google Scholar 

  7. Horsman A, Gallagher JC, Simpson M, Nordin BE. Prospective trial of oestrogen and calcium in postmenopausal women. BMJ 1977; 2: 789–92.

    Article  PubMed  CAS  Google Scholar 

  8. Aloia JF, Vaswani A, Yeh JK, Ross PL, Flaster E, Dilmanian FA. Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss. Ann Intern Med 1994; 120: 97–103.

    PubMed  CAS  Google Scholar 

  9. Lindsay R, Hart DM, Clark DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 1984; 63: 759–62.

    PubMed  CAS  Google Scholar 

  10. Lufkin EG, Wahner HW, O’Fallon WM, Hodgson SF, Kotowicz MA, Lane AW, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117: 1–9.

    PubMed  CAS  Google Scholar 

  11. Stevenson JC, Cust MP, Gangar KF, Hillard TC, Lees B, Whitehead MI. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 1990; 336: 265–9.

    Article  PubMed  CAS  Google Scholar 

  12. The writing group for the PEPI trial. Effects of hormone therapy on bone mineral density; results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996; 276: 1389–96.

    Article  Google Scholar 

  13. Adami S, Suppi R, Bertoldo F, Rossini M, Residori M, Maresca V, et al. Transdermal estradiol in the treatment of postmenopausal bone loss. Bone Miner 1989; 7: 79–86.

    Article  PubMed  CAS  Google Scholar 

  14. Christiansen C, Riis BJ. 17β-Estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab 1990; 71: 836–41.

    Article  PubMed  CAS  Google Scholar 

  15. Christiansen C, Riis BJ. Five years with continuous combined oestrogen/progestogen therapy. Effects on calcium metabolism, lipoproteins, and bleeding pattern. Br J Obstet Gynecol 1990; 97: 1087–92.

    Article  CAS  Google Scholar 

  16. Evans SF, Davie MWJ. Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post-menopausal ages. Clin Endocrinol 1996; 44: 79–84.

    Article  CAS  Google Scholar 

  17. Ettinger B, Genant HK, Steiger P, Madvig P. Low-dosage micronized 17β-estradiol prevents bone loss in postmenopausal women. Am J Obstet Gynecol 1992; 166: 479–88.

    PubMed  CAS  Google Scholar 

  18. Horsman A, Nordin BE, Gallagher JC, Kirby PA, Milner RM, Simpson M. Observations of sequential changes in bone mass in postmenopausal women: a controlled trial of oestrogen and calcium therapy. Calcif Tissue Res 1977;22 Supp1:217–24.

    Article  PubMed  Google Scholar 

  19. Kohrt WM, Birge SJ. Differential effects of estrogen treatment on bone mineral density of the spine, hip, wrist and total body in late postmenopausal women. Osteoporos Int 1995; 5: 150–5.

    Article  PubMed  CAS  Google Scholar 

  20. Lindsay R, Tohme JF. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol 1990; 76: 290–5.

    PubMed  CAS  Google Scholar 

  21. Luciano AA, De Souza MJ, Roy MP, Schoenfeld MJ, Nulsen JC, Halvorson CV. Evaluation of low-dose estrogen and progestin therapy in postmenopausal women. A double-blind, prospective study of sequential versus continuous therapy. J Reprod Med 1993; 38: 207–14.

    PubMed  CAS  Google Scholar 

  22. MacLennan AH, MacLennan A, Wenzel S, Chambers HM, Eckert K. Continuous low-dose oestrogen and progestogen hormone replacement therapy: a randomised trial. Med J Aust 1993; 159: 102–6.

    PubMed  CAS  Google Scholar 

  23. Meschia M, Brincat M, Barbacini P, Crossignani PG, Albisetti W. A clinical trial on the effects of a combination of elcatonin (carbocalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women. Calcif Tissue Int 1993; 53: 17–20.

    Article  PubMed  CAS  Google Scholar 

  24. Resch H, Pietschmann P, Krexner E, Woloszczuk W, Willvonseder R. Effects of one-year hormone replacement therapy on peripheral bone mineral content in patients with osteoporotic spine fractures. Acta Endocrinol 1990; 123: 14–8.

    PubMed  CAS  Google Scholar 

  25. Ribot C, Tremollieres F, Pouilles JM. Effect of l7β-oestradiol and norethisterone acetate on vertebral bone mass and lipid metabolism in early postmenopausal women. Maturitas 1992; 15: 217–23.

    Article  PubMed  CAS  Google Scholar 

  26. Ribot C, Tremollieres F, Pouilles JM, Louvet JP, Peyron R. Preventive effects of transdermal administration of 17β-estradiol on postmenopausal bone loss: a 2-year prospective study. Obstet Gynecol 1990; 75: 44S - 6S.

    Google Scholar 

  27. Riis BJ, Johansen J, Christiansen C. Continuous oestrogen-progestogen treatment and bone metabolism in post-menopausal women. Maturitas 1988; 10: 51–88.

    Article  PubMed  CAS  Google Scholar 

  28. Steiniche T, Hasling C, Charles P, Eriksen EF, Mosekilde L, Melsen F. A randomized study on the effects of estrogen/gestagen or high dose oral calcium on trabecular bone remodeling in postmenopausal osteoporosis. Bone 1989; 10: 313–20.

    Article  PubMed  CAS  Google Scholar 

  29. Webber CE, Blake JM, Chambers LF, Roberts JG. Effects of 2 years of hormone replacement upon bone mass, serum lipids and lipoproteins. Maturitas 1994; 19: 13–23.

    Article  PubMed  CAS  Google Scholar 

  30. Ettinger B, Genant HK, Cann CE. Postmenopausal bone loss is proven with low-dosage estrogen with calcium. Ann Intern Med 1987; 106: 40–4.

    PubMed  CAS  Google Scholar 

  31. Haines CJ, Chung TK, Leung PC, Hsu SY, Leung DH. Calcium supplementation and bone mineral density in postmenopausal women using estrogen replacement therapy. Bone 1995; 16: 529–31.

    Article  PubMed  CAS  Google Scholar 

  32. Field CS, Ory SJ, Wahner HW, Herrmann RR, Judd HL, Riggs BL. Preventive effects of transdermal 17β-estradiol on osteoporotic changes after surgical menopause: a two-year placebo-controlled trial. Am J Obstet Gynecol 1993; 168: 114–21.

    PubMed  CAS  Google Scholar 

  33. Fioretti P, Gambacciani M, Spinetti A, Cagnacci A, Paoletti AM, Felipetto R, et al. Prevention of postmenopausal bone loss and endometrial responses during a two year prospective study with transdermal 17β-estradiol and oral medroxyprogesterone acetate. Ann NY Acad Sci 1991; 622: 302–6.

    Article  PubMed  CAS  Google Scholar 

  34. Genant HK, Cann CE, Ettinger B, Gordan GS. Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy. Ann Intern Med 1982; 97: 699–705.

    PubMed  CAS  Google Scholar 

  35. Lindsay R, Hart DM, Forrest C, Baird C. Prevention of spinal osteoporosis in oophorectomised women. Lancet 1980; 2: 1151–4.

    Article  PubMed  CAS  Google Scholar 

  36. Palacios S, Menedez C, Jurado AR, Vargas JC. Effects of percutaneous oestradiol versus oral oestrogens on bone density. Maturitas 1995; 20: 209–13.

    Article  Google Scholar 

  37. Prince RL, Smith M, Dick IM, Price RI, Webb PG, Henderson NK, et al. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy. N Engl J Med 1991; 325: 1189–95.

    Article  PubMed  CAS  Google Scholar 

  38. Recker RR, Saville PD, Heaney RP. Effect of estrogens and calcium carbonate on bone loss in postmenopausal women. Ann Intern Med 1977; 87: 649–55.

    PubMed  CAS  Google Scholar 

  39. Overgaard K. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study. Calcif Tissue Int 1994; 55: 82–6.

    Article  PubMed  CAS  Google Scholar 

  40. Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992; 305: 556–61.

    Article  PubMed  CAS  Google Scholar 

  41. Overgaard K, Riis BJ, Christiansen C, Podenphant J, Johansen JS. Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol 1989; 30: 435–42.

    Article  CAS  Google Scholar 

  42. Reginster JY, Deroisy R, Lesart MP, Sarlet N, Zegels B, Jupsin I, et al. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. Am J Med 1995; 98: 452–8.

    Article  PubMed  CAS  Google Scholar 

  43. Thamsborg G, Jensen JEB, Kollerup G, Hauge EM, Melsen F, Sorensen OH. Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis. Bone 1996; 18: 207–12.

    Article  PubMed  CAS  Google Scholar 

  44. Thamsborg G, Storm TL, Sykulski R, Brinch E, Nielsen HK, Sorensen OH. Effect of different doses of nasal calcitonin on bone mass. Calcif Tissue Int 1991; 48: 302–7.

    Article  PubMed  CAS  Google Scholar 

  45. Ellerington MC, Hillard TC, Whitcroft SIJ, Marsh MS, Lees B, Banks LM, et al. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. Calcif Tissue Int 1996; 59: 6–11.

    Article  PubMed  CAS  Google Scholar 

  46. Eddy DM, Johnston C, Cummings SR, Dawson-Hughes B, Lindsay R, Melton LJ, et al. Guideline for the prevention, diagnosis, and treatment of osteoporosis: cost-effectiveness analysis and review of the evidence. Osteoporos Int In press.

    Google Scholar 

Download references

Authors
  1. Jeri W. Nieves
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lorraine Komar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Felicia Cosman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert Lindsay
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University Hospital, CHUV, CH-1011, Lausanne, Switzerland

    Peter Burckhardt M.D.

  2. USDA Nutrition Center at Tufts, 711 Washington Street, 02111, Boston, MA, USA

    Bess Dawson-Hughes M.D.

  3. The Clayton Foundation, Creighton University, 601 N. 30th Street, Suite 4841, 68131, Omaha, NE, USA

    Robert P. Heaney M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag New York, Inc.

About this chapter

Cite this chapter

Nieves, J.W., Komar, L., Cosman, F., Lindsay, R. (1998). Interactions Between Calcium Intake and Antiresorptive Therapy in Osteoporosis. In: Burckhardt, P., Dawson-Hughes, B., Heaney, R.P. (eds) Nutritional Aspects of Osteoporosis. Proceedings in the Serono Symposia USA Series. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-2228-6_34

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-2228-6_34

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4612-7463-6

  • Online ISBN: 978-1-4612-2228-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation